The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I., Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,537
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1248 · Cited by 2,312
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Self-citationOzols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
du Bois, A., Reuss, A., Pujade‐Lauraine, E., Harter, P., Ray‐Coquard, I., & Pfisterer, J. (2009) · Cancer · doi:10.1002/cncr.24149 · Cited by 1,638
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations
Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., van't Veer, L., Garber, J. E., Evans, G., Isaacs, C., Daly, M. B., Matloff, E., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012158 · Cited by 1,465
Aghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
HEINTZ, A., ODICINO, F., MAISONNEUVE, P., QUINN, M., BENEDET, J., CREASMAN, W., NGAN, H., PECORELLI, S., & BELLER, U. (2006) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(06)60033-7 · Cited by 1,277
Cancer incidence and mortality in Europe, 2004
Boyle, P., & Ferlay, J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi098 · Cited by 1,217
Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,180
Cancer incidence and mortality in Europe
Levi, F., Maisonneuve, P., Filiberti, R., La Vecchia, C., & Boyle, P. (1989) · Sozial- und Präventivmedizin · doi:10.1007/bf02148558 · Cited by 968
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
Markman, M., Rothman, R., Hakes, T., Reichman, B., Hoskins, W., Rubin, S., Jones, W., Almadrones, L., & Lewis, J. L. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.389 · Cited by 839
Menon, U., Gentry-Maharaj, A., Hallett, R., Ryan, A., Burnell, M., Sharma, A., Lewis, S., Davies, S., Philpott, S., Lopes, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70026-9 · Cited by 829
Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G., Kimmig, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0913 · Cited by 754
Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program
Brose, M. S. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1365 · Cited by 728
Katsumata, N., Yasuda, M., Takahashi, F., Isonishi, S., Jobo, T., Aoki, D., Tsuda, H., Sugiyama, T., Kodama, S., Kimura, E., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61157-0 · Cited by 727
Bookman, M. A., Brady, M. F., McGuire, W. P., Harper, P. G., Alberts, D. S., Friedlander, M., Colombo, N., Fowler, J. M., Argenta, P. A., De Geest, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1684 · Cited by 705
Self-citationvan der Burg, M. E. L., van Lent, M., Buyse, M., Kobierska, A., Colombo, N., Favalli, G., Lacave, A. J., Nardi, M., Renard, J., & Pecorelli, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321002 · Cited by 705
Self-citationHistological Typing of Ovarian Tumours
Scully, R. E. (1999) · Springer eBooks · doi:10.1007/978-3-642-58564-7 · Cited by 654
Vasey, P. A., Jayson, G. C., Gordon, A., Gabra, H., Coleman, R., Atkinson, R., Parkin, D., Paul, J., Hay, A., Kaye, S. B., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh323 · Cited by 632
Rustin, G. J. S., Vergote, I., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., du Bois, A., Kristensen, G., Jakobsen, A., Sagae, S., et al. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e3182070f17 · Cited by 625
Vergote, I., De Brabanter, J., Fyles, A., Bertelsen, K., Einhorn, N., Sevelda, P., Gore, M. E., Kærn, J., Verrelst, H., Sjövall, K., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03590-x · Cited by 623
van der Burg, M. E. L., van Lent, M., Buyse, M., Kobierska, A., Colombo, N., Favalli, G., Lacave, A. J., Nardi, M., Renard, J., & Pecorelli, S. (1995) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199507000-00012 · Cited by 578
Self-citationPujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P. A., Volgger, B., Vergote, I., Pignata, S., Ferrero, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7519 · Cited by 575
Vang, R., Shih, I.-M., & Kurman, R. J. (2009) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181b4fffa · Cited by 562
(1995) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(95)90219-8 · Cited by 553
Hoskins, W. J., Bundy, B. N., Thigpen, J. T., & Omura, G. A. (1992) · Gynecologic Oncology · doi:10.1016/0090-8258(92)90100-w · Cited by 544
McCluggage, W. G. (2011) · Pathology · doi:10.1097/pat.0b013e328348a6e7 · Cited by 497
Panici, P. B., Maggioni, A., Hacker, N., Landoni, F., Ackermann, S., Campagnutta, E., Tamussino, K., Winter, R., Pellegrino, A., Greggi, S., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji102 · Cited by 465
Kurman, R. J., & Shih, I.-M. (2008) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e318161e4f5 · Cited by 460
Frank, T. S., Manley, S. A., Olopade, O. I., Cummings, S., Garber, J. E., Bernhardt, B., Antman, K., Russo, D., Wood, M. E., Mullineau, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2417 · Cited by 455
Neijt, J. P., Engelholm, S. A., Tuxen, M. K., Sørensen, P. G., Hansen, M., Sessa, C., de Swart, C. A. M., Hirsch, F. R., Lund, B., & van Houwelingen, H. C. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3084 · Cited by 428
Self-citationTrabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, E., Lisyanskaya, A. S., Makhson, A. N., Rolski, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4037 · Cited by 395
Modan, B., Hartge, P., Hirsh-Yechezkel, G., Chetrit, A., Lubin, F., Beller, U., Ben-Baruch, G., Fishman, A., Menczer, J., Struewing, J. P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107263450401 · Cited by 385
Whittemore, A. S., Gong, G. D., & Itnyre, J. (1997) · PubMed · Cited by 383
Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis
Bristow, R. E., Puri, I., & Chi, D. S. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.08.033 · Cited by 374
[Prognostic factors in patients with stage I epithelial ovarian cancer].
Wen, H. W., & Liu, S. W. (1994) · PubMed · Cited by 353
Histopathologic Grading of Ovarian Carcinoma: A Review and Proposal
Silverberg, S. G. (2000) · International Journal of Gynecological Pathology · doi:10.1097/00004347-200001000-00003 · Cited by 351
Carlson, J. W., Miron, A., Jarboe, E. A., Parast, M. M., Hirsch, M. S., Lee, Y., Muto, M. G., Kindelberger, D., & Crum, C. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.4814 · Cited by 347
Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study
Hankinson, S. E. (1993) · JAMA · doi:10.1001/jama.270.23.2813 · Cited by 330
Bonome, T., Lee, J.-Y., Park, D.-C., Radonovich, M., Pise-Masison, C., Brady, J., Gardner, G. J., Hao, K., Wong, W. H., Barrett, J. C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2240 · Cited by 319
Bell, J., Brady, M. F., Young, R. C., Lage, J., Walker, J. L., Look, K. Y., Rose, G. S., & Spirtos, N. M. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.06.013 · Cited by 307
Neijt, J. P., ten Bokkel Huinink, W. W., van der Burg, M. E., van Oosterom, A. T., Willemse, P. H., Heintz, A. P., van Lent, M., Trimbos, J. B., Bouma, J., & Vermorken, J. B. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.8.1157 · Cited by 305
ICON1 (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.125 · Cited by 287
Fallopian tube precursors of ovarian low‐ and high‐grade serous neoplasms
Vang, R., Shih, I., & Kurman, R. J. (2013) · Histopathology · doi:10.1111/his.12046 · Cited by 281
Vernooij, F., Heintz, P., Witteveen, E., & van der Graaf, Y. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.02.030 · Cited by 280
Mackay, H. J., Brady, M. F., Oza, A. M., Reuss, A., Pujade-Lauraine, E., Swart, A. M., Siddiqui, N., Colombo, N., Bookman, M. A., Pfisterer, J., et al. (2010) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181dd0110 · Cited by 271
Self-citationMRI, CT, and PET/CT for Ovarian Cancer Detection and Adnexal Lesion Characterization
Iyer, V. R., & Lee, S. I. (2010) · American Journal of Roentgenology · doi:10.2214/ajr.09.3522 · Cited by 263
Lerner, J. P., Timor-Tritsch, I. E., Federman, A., & Abramovich, G. (1994) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(13)70284-9 · Cited by 261
Histologic Subtypes of Ovarian Carcinoma: An Overview
Soslow, R. A. (2008) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31815ea812 · Cited by 258
Shimizu, Y., Kamoi, S., Amada, S., Akiyama, F., & Silverberg, S. G. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980301)82:5<893::aid-cncr14>3.0.co;2-w · Cited by 254
Mucinous tumors of the ovary: a review.
Hart, W. R. (2005) · PubMed · Cited by 246
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum
Schmeler, K. M., Sun, C. C., Bodurka, D. C., T. Deavers, M., Malpica, A., Coleman, R. L., Ramirez, P. T., & Gershenson, D. M. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.11.013 · Cited by 245
Pignata, S., Scambia, G., Ferrandina, G., Savarese, A., Sorio, R., Breda, E., Gebbia, V., Musso, P., Frigerio, L., Del Medico, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8566 · Cited by 229
Clinical Trials in Recurrent Ovarian Cancer
Friedlander, M., Trimble, E., Tinker, A., Alberts, D., Avall-Lundqvist, E., Brady, M., Harter, P., Pignata, S., Pujade-Lauraine, E., Sehouli, J., et al. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31821bb8aa · Cited by 224
Self-citationThe Reduction in Risk of Ovarian Cancer Associated with Oral-Contraceptive Use
LEE, N. C., WINGO, P. A., GWINN, M. L., RUBIN, G. L., KENDRICK, J. S., WEBSTER, L. A., & ORY, H. W. (1987) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-198710000-00016 · Cited by 217
Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer
Lawrie, T. A., Winter-Roach, B. A., Heus, P., & Kitchener, H. C. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004706.pub5 · Cited by 204
McGowan, L., Lesher, L. P., Norris, H. J., & Barnett, M. (1985) · PubMed · Cited by 169
Bolis, G., Colombo, N., Pecorelli, S., Torri, V., Marsoni, S., Bonazzi, C., Chiari, S., Favalli, G., Mangili, G., Presti, M., et al. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059355 · Cited by 169
Self-citationChan, J. K., Tian, C., Fleming, G. F., Monk, B. J., Herzog, T. J., Kapp, D. S., & Bell, J. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.10.073 · Cited by 167
Poveda, A., Vergote, I., Tjulandin, S., Kong, B., Roy, M., Chan, S., Filipczyk-Cisarz, E., Hagberg, H., Kaye, S. B., Colombo, N., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq352 · Cited by 163
Self-citationHakes, T. B., Chalas, E., Hoskins, W. J., Jones, W. B., Markman, M., Rubin, S. C., Chapman, D., Almadrones, L., & Lewis, J. L. (1992) · Gynecologic Oncology · doi:10.1016/0090-8258(92)90305-3 · Cited by 162
Reclassification of serous ovarian carcinoma by a 2‐tier system: A Gynecologic Oncology Group Study
Bodurka, D. C., Deavers, M. T., Tian, C., Sun, C. C., Malpica, A., Coleman, R. L., Lu, K. H., Sood, A. K., Birrer, M. J., Ozols, R., et al. (2012) · Cancer · doi:10.1002/cncr.26618 · Cited by 160
Fruscio, R., Corso, S., Ceppi, L., Garavaglia, D., Garbi, A., Floriani, I., Franchi, D., Cantù, M. G., Bonazzi, C. M., Milani, R., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds241 · Cited by 159
Self-citationBertelsen, K., Jakobsen, A. K. M., Strøyer, I., Nielsen, K. V., Sandberg, E., ANDERSEN, J. E., AHRONS, S., Nyland, M., Pedersen, P. H., Larsen, G., et al. (1993) · Gynecologic Oncology · doi:10.1006/gyno.1993.1081 · Cited by 152
Cantù, M. G., Buda, A. A., Parma, G., Rossi, R., Floriani, I., Bonazzi, C. M., Dell’Anna, T., Torri, V., & Colombo, N. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1232 · Cited by 147
Self-citationp53 Mutations and Expression in Ovarian Cancers: Correlation with Overall Survival
Wen, W., Reles, A., Runnebaum, I. B., Sullivan‐Halley, J., Bernstein, L., Jones, L. A., Felix, J. C., Kreienberg, R., El‐Naggar, A. K., & Press, M. F. (1999) · International Journal of Gynecological Pathology · doi:10.1097/00004347-199901000-00005 · Cited by 143
Zang, R., Harter, P., S., D., Sehouli, J., Jiang, R., Trope, C. G., Ayhan, A., Cormio, G., Xing, Y., Wollschlaeger, K., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.328 · Cited by 135
Self-citationCass, I. A., Li, A. J., Runowicz, C. D., Fields, A. L., Goldberg, G. L., Leuchter, R. S., Lagasse, L. D., & Karlan, B. Y. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2000.6027 · Cited by 127
Ovarian low-grade serous carcinoma: A comprehensive update
Díaz-Padilla, I., Malpica, A. L., Minig, L., Chiva, L. M., Gershenson, D. M., & González-Martín, A. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.04.029 · Cited by 126
Lambert, H. E., Rustin, G. J. S., Gregory, W. M., & Nelstrop, A. E. (1997) · Annals of Oncology · doi:10.1023/a:1008256431090 · Cited by 119
Prognostic factors for survival in Stage I epithelial ovarian carcinoma
Sevelda, P., Vávra, N., SCHEMPER, M., & Salzer, H. (1990) · Cancer · doi:10.1002/1097-0142(19900515)65:10<2349::aid-cncr2820651031>3.0.co;2-# · Cited by 111
Fg, L., Cw, R., Dm, L., et al. (1989) · PubMed · Cited by 109
Tropé, C., Kærn, J., Högberg, T., Abeler, V. M., Hagen, B., Kristensen, G. B., Onsrud, M., Pettersen, E. O., Rosenberg, P., Sandvei, R., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008399414923 · Cited by 108
Hess, L. M., Benham-Hutchins, M. M., Herzog, T. J., Hsu, C., Malone, D., Skrepnek, G., Slack, M., & Ds, A. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2006.00846.x · Cited by 88
Fotopoulou, C., Zang, R., Gültekin, M., Cibula, D., Ayhan, A., Liu, D., Richter, R., Braicu, E. I., Mahner, S., Harter, P., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2673-z · Cited by 77
Self-citationAdjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer
Winter-Roach, B. A., Kitchener, H. C., & Dickinson, H. O. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004706.pub3 · Cited by 76
Understanding the problem of inadequately staging early ovarian cancer
Timmers, P. J., Zwinderman, A. H., Coens, C., Vergote, I. B., & Trimbos, J. B. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.012 · Cited by 49
Rustin, G. J. S., & van der Burg, M. E. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18_suppl.1 · Cited by 47
Cited by
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Self-citationOlaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., Fujiwara, K., Vergote, I., Colombo, N., Mäenpää, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911361 · Cited by 2,055
Self-citationBreast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442
Self-citationGarcia, J., Hurwitz, H. I., Sandler, A. B., Miles, D., Coleman, R. L., Deurloo, R., & Chinot, O. L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102017 · Cited by 1,159
Metadata
- Authors
- Ledermann, J. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., & Sessa, C.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 24
- Issue
- Suppl 4
- Pages
- vi24-vi32
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2162645859
- Cited by
- 1,104
- References
- 87
- FWCI
- 66.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.